The British Standards Institute has given CE Marking to Ventracor for its VentrAssist left ventricular assist device (LVAD), allowing the company to market and sell the device throughout Europe.
Ventracor CEO Peter Crosby stated that his company will continue its drive to develop strong clinical data published in reputable scientific journals by key opinion leaders, which is essential to build market acceptance that will drive future sales.
VentrAssist is the focus of the BRACE clinical study for which three new medical centers have enrolled their first VentrAssist patients, bringing the total VentrAssist clinical experience to nearly 80 patients at 12 centers worldwide.
In the US, the University of Minnesota Hospitals and Clinics in Minneapolis treated a patient under the U.S. Feasibility Trial.
June 19, 2024 
